Evidence map›Paper›PMID 34484443›Full record

ArticleAnnals of thoracic medicine

Pulmonary neuroendocrine carcinoid tumors: Is there a predictive role to the Ki 67 index?

Ana Karina Patané, Gabriela Guma, Mercedes Rayá, Adolfo Rosales, Walter Astorino, Moisés Rosenberg

Abstract read
In one paragraph

Article in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana Karina PatanéDepartment of Thoracic, Hospital De Rehabilitación Respiratoria María Ferrer, Alexander Fleming, Buenos Aires, Argentina.
Gabriela GumaDepartment of Pathology, Hospital De Rehabilitación Respiratoria María Ferrer, Alexander Fleming, Buenos Aires, Argentina.
Mercedes RayáDepartment of Pathology, Hospital De Rehabilitación Respiratoria María Ferrer, Alexander Fleming, Buenos Aires, Argentina.
Adolfo RosalesDepartment of Thoracic, Hospital De Rehabilitación Respiratoria María Ferrer, Alexander Fleming, Buenos Aires, Argentina.
Walter AstorinoDepartment of Thoracic Surgery and Pathology, Instituto Médico Especializado, Alexander Fleming, Buenos Aires, Argentina.
Moisés RosenbergDepartment of Thoracic Surgery and Pathology, Instituto Médico Especializado, Alexander Fleming, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere are several factors predicting evolution in carcinoid tumors (CT) to date including the Ki67 role.

aimsThe aim of this study is to identify a KI67 cut-off point for a population of CT and determine its prognostic implication in global and disease-free survival.

methodsHematoxylin-eosin slides of 102 CT were revised. The percentage of cells expressing Ki 67 was determined manually. STATISTICAL ANALYSIS: The variables were compared with the t-test or the Wilcoxon test according to their distribution, the categorical ones with Chi-square or Fisher's test. The best cut-off point was established by constructing receiver operating characteristic curves, then using that value as a dichotomous variable.

results72 typical carcinoids (TC) and 30 atypical carcinoids (AC) were analyzed; 66% were female. Median age (TC 38 vs. AC 51,

conclusionsHistological type is the best predictor of prognosis in the carcinoid tumor group. In the AC subgroup, the marginal association between mortality, frequency of relapses and Ki values 67 ≥ 1.18 has clinical relevance future analyses are required to determine the real predictive value of this variable.

Indexed as

Ki 67 indexlung carcinoidspredictive value

Identifiers

PMID34484443
PMCPMC8388565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.